Evaxion Biotech stock analysis
Want to see EVAX full AI Analyst Report?
Evaxion Biotech (EVAX) Stock Price & Analysis
EVAX Stock Chart & Stats
- Day’s Range
- $2.74 - $2.89
- 52-Week Range
- $2.65 - $6.92
- Previous Close
- $2.74
- Volume
- N/A
- Average Volume (3M)
- 109.19K
- Market Cap
- $22.85M
- Enterprise Value
- $18.96M
- Total Cash (Recent Filing)
- $14.00M
- Total Debt (Recent Filing)
- $7.10M
- Price to Earnings (P/E)
- ―
- Beta
- 2.14
- Next Earnings
- Nov 19, 2026 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Durable EVX-01 Clinical Responses
Durable three-year responses and sustained immune activity strengthen EVX-01’s clinical profile beyond an initial readout. This supports the credibility of Evaxion’s personalized vaccine approach, improves partnering potential, and provides a foundation for advancing the lead oncology asset.
AI-Immunology Platform Validation
External recognition of the AI-Immunology platform adds scientific credibility to Evaxion’s technology and may improve visibility with partners. Platform validation is potentially durable because the same discovery capabilities support multiple oncology, infectious-disease, and autoimmune programs.
Broader Pipeline And Strategic Reach
Expansion into glioblastoma broadens Evaxion’s opportunity set beyond its lead melanoma program and applies its antigen-discovery platform to another high-unmet-need cancer. The Duke collaboration also adds specialized clinical expertise for development of EVX-05.
Bears Say
Persistent Unprofitable Operations
Continued losses and no reported revenue show that Evaxion has not yet established a self-sustaining commercial model. Ongoing R&D investment is necessary for pipeline progress, but the absence of operating profitability leaves earnings dependent on future clinical and business-development success.
Negative Cash Generation And Funding Dependence
Persistent negative operating and free cash flow means the company cannot currently fund development from internal operations. Continued cash consumption increases reliance on financing or partnerships, leaving future program execution sensitive to capital availability and funding conditions.
Equity Financing And Development Uncertainty
Recent ATM issuance provides funding but expands the share base and can dilute existing holders. At the same time, important programs remain preclinical or dependent on regulatory and CMC milestones, making the timing and value of future pipeline progress uncertain.
Evaxion Biotech News
Evaxion Biotech presents three-year immune and clinical outcome data for EVX-01
Evaxion announced new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma. The data demonstrates EVX-01 inducing an immune response in all patients,
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
What is Evaxion Biotech’s market cap?
When is Evaxion Biotech’s upcoming earnings report date?
How were Evaxion Biotech’s earnings last quarter?
Is Evaxion Biotech overvalued?
Does Evaxion Biotech pay dividends?
What is Evaxion Biotech’s EPS estimate?
How many shares outstanding does Evaxion Biotech have?
What happened to Evaxion Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Evaxion Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen Katrina Tayton-Martin
- Employees
- 46
- Website
- evaxion.ai
- Address
- Dr. Neergaards Vej, Horsholm, ND, 2970, DK
Evaxion Biotech (EVAX) Earnings & Revenues
EVAX Company Deck
EVAX Earnings Call
Earnings Call SentimentPositive
The call emphasized substantial scientific and platform progress (strong EVX-01 immunogenicity and response data, new EVX-05 program, EVX-04 and EVX-V1 advances, and external validation of the personalized vaccine field). Financial discipline was highlighted and the cash runway was reconfirmed into H2 2027, with an ATM activated for optionality. Offsetting risks include a modest cash balance ($14.0M), a quarterly net loss of $3.7M, reliance on ATM/partnerships to extend runway, and early-stage status/timeline uncertainty for key new programs (EVX-05) and pending IND-enabling/CMC work for EVX-04.
View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |












